Citadel Advisors’s Lux Health Tech Acquisition Corp. Class A Common Stock LUXA Stock Holding History

Citadel Advisors’s Portfolio LUXA Stock Details LUXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39,200	Closed	-$392K	–	16000
2022 Q3	$392K	Sell	39,200 -41,000	-51%	-$408K	﹤0.01%	8993
2022 Q2	$793K	Buy	80,200 +23,900	+42%	+$236K	﹤0.01%	7566
2022 Q1	$555K	Sell	56,300 -16,100	-22%	-$158K	﹤0.01%	9135
2021 Q4	$710K	Buy	72,400 +39,700	+121%	+$391K	﹤0.01%	8800
2021 Q3	$321K	Buy	32,700 +5,900	+22%	+$58.1K	﹤0.01%	10918
2021 Q2	$265K	Buy	+26,800	New	+$270K	﹤0.01%	11575

Citadel Advisors's LUXA Position: Q3 2022 in Review

Citadel Advisors sold out of Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA) in Q3 2022, closing a stake of 39,525 shares — an estimated $393K sold.

Citadel Advisors first reported a position in LUXA in Q3 2021 and held it in 3 quarters. The position peaked at $391K in Q2 2022. 72 funds tracked by Wall St. Rank hold LUXA as of Q3 2022.

Citadel Advisors reported no remaining Lux Health Tech Acquisition Corp. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 39,525 Lux Health Tech Acquisition Corp. Class A Common Stock shares in Q3 2022, an estimated $393K.
Citadel Advisors first reported a position in Lux Health Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 3 quarters.
Citadel Advisors's Lux Health Tech Acquisition Corp. Class A Common Stock position peaked at $391K in Q2 2022.
72 funds tracked by Wall St. Rank held Lux Health Tech Acquisition Corp. Class A Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.